Pyrotinib in Combination With Letrozole in Patients With HER2-Positive, ER-Positive Metastatic Breast Cancer
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
This is a prospective, single-arm, multi-center clinical study of pyrotinib in combination
With letrozole in patients With HER2-Positive, ER-Positive metastatic breast cancer. Our aim
was to explore the efficacy and safety of pyrotinib combined with letrozole in patients with
HER2-positive, ER-positive metastatic breast cancer.